EXEL vs GILD
Exelixis, Inc. (EXEL) and Gilead Sciences, Inc. (GILD) are both filed with the SEC under Biological Products, (No Diagnostic Substances). GILD is 13.5× EXEL's size by market cap ($184.6B against $13.7B); EXEL trades at the higher fiscal-year P/E (31.4× against 22.0×); EXEL reports the higher net margin (33.7% against 28.9%); EXEL grew sales faster over three years (+12.9% against +2.6%); and over the past year EXEL returned +43.7% against GILD's +31.9%.
| EXEL | GILD | |
|---|---|---|
| Last close | $54.45 | $145.68 |
| Market cap | $13.7B | $184.6B |
| P/E (FY) | 31.4× | 22.0× |
| P/S | 5.9× | 6.3× |
| Operating margin | 37.6% | 34.0% |
| Net margin | 33.7% | 28.9% |
| Return on equity | 35.5% | 40.5% |
| Sales growth (3y) | +12.9% | +2.6% |
| EPS growth (3y) | +70.6% | +23.0% |
| Dividend yield | — | 2.2% |
| 1-year return | +43.7% | +31.9% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: EXEL FY2026 (ended 2026-01-02); GILD FY2025 (ended 2025-12-31). — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| EXEL | GILD | |
|---|---|---|
| Institutional holders (13F) | 693 | 2,295 |
| Insider buyers − sellers (180d) | -5 | -3 |
| Congressional trades disclosed (180d) | 0 | 3 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 10 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
EXEL vs GILD: common questions
- Is EXEL bigger than GILD?
- GILD carries the larger market cap — $184.6B against $13.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, EXEL or GILD?
- EXEL, at a fiscal-year 31.4× against 22.0× for GILD. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have EXEL and GILD performed over the past year?
- EXEL returned +43.7% and GILD +31.9%, measured on the trailing calendar year to the last close.
- How many institutions hold EXEL and GILD?
- 693 13F filers report a position in EXEL and 2,295 in GILD, on the latest quarter in the panel.
- Are EXEL and GILD in the same industry?
- Both are filed with the SEC under Biological Products, (No Diagnostic Substances), which is the classification this pairing is built on.
EXEL overview → · GILD overview → · EXEL institutional ownership → · GILD institutional ownership → · Congress and GILD → · Executive branch and GILD →
More in Biological Products, (No Diagnostic Substances): AMGN vs BIIB · AMGN vs EXEL · AMGN vs GILD · AMGN vs HALO
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/exel-vs-gild